KEYNOTE-426: Pembrolizumab and axitinib vs sunitinib in advanced renal cell carcinoma

Bookmark and Share
Published: 14 Feb 2019
Views: 2075
Prof Brian Rini - Cleveland Clinic, Cleveland, USA

Prof Brian Rini speaks to ecancer at the 2019 ASCO Genitourinary Cancers Symposium about the KEYNOTE-426 trial.

He outlines the 'astounding' results from this trial, with a high survival and response rate from the pembrolizumab plus VEGF-targeted therapy (axitinib).